Abbott Xinlay Not Ready For Approval Or Abandonment, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Oncologic Drugs Advisory Committee unanimously recommends against approval of Abbott's prostate cancer therapy atrasentan.
You may also be interested in...
Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
Xinlay Phase III Back-Up Trial Winding Down
Abbott expects to have data by year-end on which to base a regulatory strategy for the prostate cancer drug.
Xinlay Phase III Back-Up Trial Winding Down
Abbott expects to have data by year-end on which to base a regulatory strategy for the prostate cancer drug.